4 results match your criteria: "Division of Cardiology Duke University Durham NC.[Affiliation]"
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.
J Am Heart Assoc
September 2024
Population Health Research Institute, McMaster University Hamilton Canada.
Background: Despite oral anticoagulation, patients with atrial fibrillation (AF) remain at risk of ischemic stroke and systemic embolism (SE) events. For patients whose residual risk is sufficiently high, additional therapies might be useful to mitigate stroke risk.
Methods And Results: Individual patient data from 5 landmark trials testing oral anticoagulation in AF were pooled in A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in AF (COMBINE AF).
Article Synopsis
- Cardiogenic shock remains a critical health issue with high mortality rates, and no significant new treatments have emerged in decades, making management difficult.
- A collaborative, multidisciplinary approach involving specialized "shock teams" is being promoted to improve patient outcomes in high-volume clinical settings.
- The proposal aims to establish a Cardiogenic Shock Team Collaborative to enhance care protocols, education, and overall performance, similar to successful initiatives in other medical areas.
Background Heart failure with preserved ejection fraction (HFpEF) constitutes half of hospitalized heart failure cases and is commonly associated with obesity. The role of natriuretic peptide levels in hospitalized obese patients with HFpEF, however, is not well defined. We sought to evaluate change in NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels by obesity category and related clinical outcomes in patients with HFpEF hospitalized for acute heart failure.
View Article and Find Full Text PDFBackground There are sex differences in the efficacy and safety of aspirin for the prevention of myocardial infarction and stroke. Whether this is explained by underlying differences in platelet reactivity and aspirin response remains poorly understood. Methods and Results Healthy volunteers (n=378 208 women) and patients with coronary artery disease or coronary artery disease risk factors (n=217 112 women) took aspirin for 4 weeks.
View Article and Find Full Text PDF